Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Moving Beyond Gleason Scoring.

Miles B, Ittmann M, Wheeler T, Sayeeduddin M, Cubilla A, Rowley D, Bu P, Ding Y, Gao Y, Lee M, Ayala GE.

Arch Pathol Lab Med. 2019 May;143(5):565-570. doi: 10.5858/arpa.2018-0242-RA. Epub 2019 Mar 13.

PMID:
30865488
2.

Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE.

Hum Pathol. 2008 Feb;39(2):282-91. doi: 10.1016/j.humpath.2007.04.025.

PMID:
18206496
3.

Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE.

Hum Pathol. 2007 Nov;38(11):1611-20. Epub 2007 Sep 14.

PMID:
17868773
4.

PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).

Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W.

Prostate. 2019 May 21. doi: 10.1002/pros.23831. [Epub ahead of print]

PMID:
31111513
5.

Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.

Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR.

Am J Pathol. 2011 Jan;178(1):79-87. doi: 10.1016/j.ajpath.2010.09.042. Epub 2010 Dec 23.

6.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
7.

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA.

Eur Urol. 2016 Mar;69(3):428-35. doi: 10.1016/j.eururo.2015.06.046. Epub 2015 Jul 10.

8.

Contemporary grading for prostate cancer: implications for patient care.

Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI.

Eur Urol. 2013 May;63(5):892-901. doi: 10.1016/j.eururo.2012.10.015. Epub 2012 Oct 17. Review.

PMID:
23092544
9.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
10.

Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3).

De Vivar AD, Sayeeduddin M, Rowley D, Cubilla A, Miles B, Kadmon D, Ayala G.

Hum Pathol. 2017 May;63:202-211. doi: 10.1016/j.humpath.2017.02.019. Epub 2017 Mar 15.

PMID:
28315427
11.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

12.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

13.

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee.

Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Review.

PMID:
26492179
14.

Histological grading of prostatic carcinoma in prostatectomy specimens. Comparison of prognostic accuracy of five grading systems.

Gallee MP, Ten Kate FJ, Mulder PG, Blom JH, van der Heul RO.

Br J Urol. 1990 Apr;65(4):368-75.

PMID:
2340371
15.

An update of the Gleason grading system.

Epstein JI.

J Urol. 2010 Feb;183(2):433-40. doi: 10.1016/j.juro.2009.10.046. Epub 2009 Dec 14. Review.

PMID:
20006878
16.

Recent advances in prostate cancer pathology: Gleason grading and beyond.

Shah RB, Zhou M.

Pathol Int. 2016 May;66(5):260-72. doi: 10.1111/pin.12398. Epub 2016 Mar 18. Review.

PMID:
26991008
17.

The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.

Helpap B, Ringli D, Tonhauser J, Poser I, Breul J, Gevensleben H, Seifert HH.

Pathol Oncol Res. 2016 Apr;22(2):349-56. doi: 10.1007/s12253-015-0013-x. Epub 2015 Nov 12.

PMID:
26563277
18.

The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.

Billis A, Guimaraes MS, Freitas LL, Meirelles L, Magna LA, Ferreira U.

J Urol. 2008 Aug;180(2):548-52; discussion 552-3. doi: 10.1016/j.juro.2008.04.018. Epub 2008 Jun 11.

PMID:
18550106
19.

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.

Pierorazio PM, Walsh PC, Partin AW, Epstein JI.

BJU Int. 2013 May;111(5):753-60. doi: 10.1111/j.1464-410X.2012.11611.x. Epub 2013 Mar 6.

20.

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA.

J Clin Oncol. 2009 Jul 20;27(21):3459-64. doi: 10.1200/JCO.2008.20.4669. Epub 2009 May 11.

Supplemental Content

Support Center